Monopar Therapeutics (NASDAQ:MNPR)
| Market Cap | 474.21M-13.0% |
| Revenue (ttm) | 0 |
| Net Income | -17.84M-3.1% |
| EPS | -2.34-30.7% |
| Shares Out | 6.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,416 |
| Open | 71.50 |
| Previous Close | 72.58 |
| Day's Range | 69.29 - 71.82 |
| 52-Week Range | 50.07 - 124.82 |
| Beta | 1.51 |
| Analysts | Buy |
| Price Target | 126.00(+78.34%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MNPR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MNPR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MNPR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MNPR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MNPR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MNPR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MNPR
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $12.73M |
| XBIState Street SPDR S&P Biotech ETF | $10.62M |
| IWMiShares Russell 2000 ETF | $8.40M |
| VXFVanguard Extended Market ETF | $4.26M |
| IWNiShares Russell 2000 Value ETF | $2.29M |
| VTWOVanguard Russell 2000 ETF | $2.09M |
Estimated from each fund’s disclosed top holdings × AUM
MNPR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MNPR’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score